[{"id":"5d9a2d22-a701-4304-82b2-d07cf3b47eb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01723774","created_at":"2021-01-18T07:31:32.711Z","updated_at":"2024-07-02T16:35:25.670Z","phase":"Phase 2","brief_title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","source_id_and_acronym":"NCT01723774","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PIK3CA mutation • MET mutation • PIK3CA wild-type","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PIK3CA mutation • MET mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • anastrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 04/10/2013","start_date":" 04/10/2013","primary_txt":" Primary completion: 04/13/2021","primary_completion_date":" 04/13/2021","study_txt":" Completion: 08/24/2026","study_completion_date":" 08/24/2026","last_update_posted":"2023-12-20"},{"id":"d08d0e16-df57-4b5e-a8b7-7669765049cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983107","created_at":"2023-08-09T14:09:24.430Z","updated_at":"2024-07-02T16:35:40.474Z","phase":"Phase 2","brief_title":"Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT05983107","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • PIK3CA mutation • PGR positive • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PIK3CA mutation • PGR positive • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • fulvestrant • Epidaza (chidamide) • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 07/15/2026","primary_completion_date":" 07/15/2026","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2023-08-09"},{"id":"dfbe556a-f067-4170-9719-fab615cb91ce","acronym":"NSABP FC-11","url":"https://clinicaltrials.gov/study/NCT03457896","created_at":"2021-01-18T17:02:51.051Z","updated_at":"2024-07-02T16:36:14.405Z","phase":"Phase 2","brief_title":"Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status","source_id_and_acronym":"NCT03457896 - NSABP FC-11","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • KRAS • BRAF • PIK3CA • NRAS","pipe":" | ","alterations":" HER-2 amplification • PIK3CA wild-type","tags":["HER-2 • KRAS • BRAF • PIK3CA • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Erbitux (cetuximab) • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/18/2018","start_date":" 05/18/2018","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2022-03-31"},{"id":"fef0553d-d7f6-4eee-b4b5-81263ffdda78","acronym":"","url":"https://clinicaltrials.gov/study/NCT01960023","created_at":"2021-01-18T08:53:41.440Z","updated_at":"2024-07-02T16:36:22.377Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01960023","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • KRAS • BRAF • PIK3CA • CD4","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • PIK3CA wild-type","tags":["HER-2 • KRAS • BRAF • PIK3CA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Nerlynx (neratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 07/13/2016","primary_completion_date":" 07/13/2016","study_txt":" Completion: 07/13/2016","study_completion_date":" 07/13/2016","last_update_posted":"2021-10-27"},{"id":"65d7b6af-fe8d-4710-aebb-37b321ad9a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01219699","created_at":"2021-01-18T04:53:54.581Z","updated_at":"2024-07-02T16:36:40.815Z","phase":"Phase 1","brief_title":"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene","source_id_and_acronym":"NCT01219699","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA wild-type","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 10/05/2010","start_date":" 10/05/2010","primary_txt":" Primary completion: 02/05/2015","primary_completion_date":" 02/05/2015","study_txt":" Completion: 04/16/2020","study_completion_date":" 04/16/2020","last_update_posted":"2020-09-22"},{"id":"2b092fd3-dadb-42dc-a9d2-ad094859b4e3","acronym":"NeoPHOEBE","url":"https://clinicaltrials.gov/study/NCT01816594","created_at":"2021-01-18T08:03:59.157Z","updated_at":"2024-07-02T16:36:53.700Z","phase":"Phase 2","brief_title":"NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer","source_id_and_acronym":"NCT01816594 - NeoPHOEBE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • ER negative • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • ER negative • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/03/2013","start_date":" 09/03/2013","primary_txt":" Primary completion: 02/18/2015","primary_completion_date":" 02/18/2015","study_txt":" Completion: 02/18/2015","study_completion_date":" 02/18/2015","last_update_posted":"2019-11-14"},{"id":"cda106cd-045e-456f-8140-030b6df46879","acronym":"","url":"https://clinicaltrials.gov/study/NCT01923168","created_at":"2021-01-18T08:40:53.958Z","updated_at":"2024-07-02T16:37:06.879Z","phase":"Phase 2","brief_title":"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women","source_id_and_acronym":"NCT01923168","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • letrozole • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 340","initiation":"Initiation: 03/11/2014","start_date":" 03/11/2014","primary_txt":" Primary completion: 07/07/2017","primary_completion_date":" 07/07/2017","study_txt":" Completion: 07/08/2017","study_completion_date":" 07/08/2017","last_update_posted":"2018-09-14"},{"id":"4513a8c1-94ac-4f9c-bf9b-a1b2792ab066","acronym":"LORELEI","url":"https://clinicaltrials.gov/study/NCT02273973","created_at":"2021-01-18T10:42:00.009Z","updated_at":"2024-07-02T16:37:10.619Z","phase":"Phase 2","brief_title":"A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)","source_id_and_acronym":"NCT02273973 - LORELEI","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • taselisib (GDC-0032)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 11/12/2014","start_date":" 11/12/2014","primary_txt":" Primary completion: 03/13/2017","primary_completion_date":" 03/13/2017","study_txt":" Completion: 03/13/2017","study_completion_date":" 03/13/2017","last_update_posted":"2018-05-21"}]